article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 164
article thumbnail

Enforcement or Compliance

Canna Law Blog

The issue of enforcement or compliance is probably the biggest one most states face at the policy level. Today, we’ll look at the argument that a compliance focus is better than an enforcement focus. Despite all of this, some folks seem to think that prohibition and compliance is still the answer. The enforcement v.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

Press Release: LegitScript Announces New CBD e-Commerce Certification Program to Ensure Accountability, Regulatory Compliance

Cannabis Law Report

Starting today, US manufacturers and merchants can apply through LegitScript to certify CBD products and websites that are in compliance with USDA, FDA, FTC, and DEA regulations, as well as state-specific laws.

article thumbnail

American Bar Association Urges Congress To Let States Set Their Own Marijuana Policies

SMPL

The American Bar Association (ABA) adopted a resolution on Monday that calls on Congress to allow states to set their own marijuana policies and recommends rescheduling or descheduling cannabis under federal law. One area that could be quickly improved is in the sourcing of research-grade marijuana.

Policy 40
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA).

article thumbnail

The Supreme Court Puts a Halt to a Commandeering Congress

MJ Business Attorneys

For starters, this case clarifies that the federal government can neither force the states to enforce federal marijuana policy, nor can they prohibit the states from implementing or revising their own marijuana policies. The federal government just cannot prescribe what shall be orthodox in marijuana policy.

Policy 100